miR-342 acts as a tumor suppressor and can sensitize ER-positive tumors to endocrine therapy by regulating genes involved in cell death pathways, such as gem nuclear organelle associated protein 4 (GEMIN4) and bone morphogenetic protein 7 (BMP7) [78]. The gene discussed is GEMIN4; the disease is neoplasm.